Competitive Dealmaking Market Shifts To Smaller M&A, Partnering
Acquisition Numbers Rise, Values Fall In Q1
Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.
